On June 17, 2026, Corcept Therapeutics CORT announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant, a treatment aimed at patients with Cushing’s syndrome. This resubmission follows the FDA’s request for additional analyses of the data presented in the initial NDA submission.
The resubmission of the NDA for relacorilant is a significant step for Corcept Therapeutics, as it reflects the company’s commitment to addressing the FDA’s concerns and advancing its drug development pipeline. The pivotal GRACE trial and the double-blind, placebo-controlled Phase III GRADIENT trial have shown promising results, suggesting that relacorilant could provide substantial and lasting improvements for patients suffering from Cushing’s syndrome while minimizing severe side effects associated with existing therapies.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company focused on the discovery and development of medications that modulate the effects of cortisol, a hormone linked to various severe metabolic, oncologic, and neuropsychiatric disorders. With a market capitalization of approximately $8.78 billion, the company operates within the healthcare sector, specifically in the biotechnology industry. Corcept markets Korlym (mifepristone) tablets for treating hypercortisolism and has a robust pipeline that includes several compounds under evaluation for various serious disorders.
Currently, GF Value™ data is not available for Corcept Therapeutics. However, the company’s P/E ratio stands at 233.57x, which is significantly higher than the historical median P/E ratio, indicating that the stock may be overvalued relative to its earnings. Investors should consider this high valuation in the context of the company’s growth prospects and the ongoing development of its drug pipeline. For more details, visit the CORT stock page.
The GF Score™ ranks stocks from 0 to 100 based on five key aspects: Financial Strength, Profitability, Growth, Valuation, and Momentum. Stocks with higher GF Score™ values have been found to generate higher long-term returns (backtested 2006-2021).
Corcept Therapeutics demonstrates strong financial strength with a GF Score™ of 82, indicating a solid potential for long-term returns. The company excels in profitability and growth, ranking 9/10 and 10/10, respectively. However, the high P/E ratio suggests that the stock may be overvalued, which could be a concern for potential investors. For more insights, visit the CORT stock page.
In the past three months, insiders have sold approximately $17.7 million worth of shares, with 11 insider selling transactions and no insider buying activity reported. This trend may raise concerns about the company’s outlook from those closest to it.
Corcept Therapeutics is navigating a critical phase with its NDA resubmission for relacorilant, which could significantly impact its future growth trajectory. While the company shows strong financial metrics and a promising pipeline, the high valuation and insider selling activity warrant careful consideration for potential investors. For the complete analysis, visit the CORT stock page. You can also use the GuruFocus Stock Screener to find similar opportunities.
What is CORT’s GF Score™?
CORT’s GF Score™ is 82/100, indicating strong potential for long-term returns based on its financial strength, profitability, and growth metrics.
How is CORT valued?
CORT has a P/E ratio of 233.57x, which is significantly higher than historical norms, suggesting that the stock may be overvalued relative to its earnings.
What is CORT’s P/E ratio compared to historical?
CORT’s current P/E ratio of 233.57x is close to a 5-year high, indicating that the stock may be trading at a premium compared to its historical valuation levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
We’d love to learn more about your experiences on GuruFocus.com and how we can improve!
Leave a Reply